Acalabrutinib for mantle cell lymphoma.

Antineoplastic Agents / therapeutic use Benzamides / therapeutic use Humans Lymphoma, Mantle-Cell / drug therapy Protein Kinase Inhibitors / therapeutic use Pyrazines / therapeutic use

Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
13 06 2019
Historique:
received: 04 01 2019
accepted: 11 03 2019
pubmed: 11 4 2019
medline: 10 1 2020
entrez: 11 4 2019
Statut: ppublish

Résumé

Mantle cell lymphoma (MCL) is a unique type of non-Hodgkin lymphoma characterized by the overexpression of cyclin D1. MCL patients typically live for years but experience multiple relapses. Acalabrutinib is a novel second-generation oral Bruton tyrosine kinase inhibitor approved by the US Food and Drug Administration for relapsed MCL based on a clinical trial demonstrating an overall response rate of 81%. It provides a valuable new treatment option for MCL patients and is now being tested upfront.

Identifiants

DOI: 10.1182/blood.2019852368 PMID: 30967367
pubmed: 30967367
pii: S0006-4971(20)42487-5
doi: 10.1182/blood.2019852368
doi:

Substances chimiques

Antineoplastic Agents 0
Benzamides 0
Protein Kinase Inhibitors 0
Pyrazines 0
acalabrutinib I42748ELQW

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2570-2574

Informations de copyright

© 2019 by The American Society of Hematology.

Auteurs

Thomas E Witzig (TE)

Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
ORCID: 0000-0002-4215-6500

David Inwards (D)

Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Acalabrutinib for mantle cell lymphoma.
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Hydrocarbures cycliques › Hydrocarbures aromatiques › Dérivés du benzène › Benzoates › Benzamides › Acalabrutinib for mantle cell lymphoma.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Acalabrutinib for mantle cell lymphoma.
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Lymphomes › Lymphome malin non hodgkinien › Lymphome à cellules du manteau › Acalabrutinib for mantle cell lymphoma.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › Acalabrutinib for mantle cell lymphoma.
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrazines › Acalabrutinib for mantle cell lymphoma.